Diatos S.A. Pre-Clinical Results Published in Clinical Cancer Research
Published: Apr 01, 2008
Irinotecan is an effective chemotherapeutic agent that is prescribed for advanced colorectal, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The principle side effect of irinotecan is severe (grade 3-4) diarrhoea observed in 30-40% of treated patients. A significant clinical advantage should therefore be gained from the direct administration of the active metabolite, SN38, using a drug delivery technology such as Vectocell®, which delivers higher concentrations of SN38, whilst bypassing the severe side effects.
Commenting on today’s announcement, Jonathan Kearsey, Ph.D, Director of Research at Diatos, said: “The search for cytotoxic molecules with enhanced efficacy and toxicity profiles is essential for improved cancer patient care. This peer-reviewed publication represents another step in the validation of the benefits of DTS-108 versus standard of care treatment.”
“Rapid completion of the preclinical toxicology program is expected to allow Diatos to further evaluate the benefit of DTS-108 and the Vectocell® technology platform in the clinical setting.” He added.